AURELIA ONLINEMounjaro Weight-Loss Plateau: What to Do When Weight Stops Falling, and Should You Increase the Dose?
This English page provides medical information and booking guidance. Consultation may be conducted in Japanese or English. Tell the doctor the country where you are physically located. Medication supplied through this service is received in Japan by the patient; proxy pickup and direct overseas delivery are not supported.
A weight-loss plateau while using tirzepatide is common and does not automatically mean the medicine has stopped working. Before increasing the dose, distinguish a true long-term plateau from normal weekly variation, constipation, fluid shifts or a transition into weight maintenance.
- One or two flat weeks are not enough to diagnose a true plateau.
- A 2025 SURMOUNT analysis defined plateau using repeated 12-week intervals with less than 5% weight change.
- Median time to plateau ranged from about 24.3 to 36.1 weeks depending on baseline BMI category.
- By week 72, roughly 88–90% had reached the study-defined plateau.
- Higher target doses were associated with later plateau, but even 15 mg does not prevent plateau indefinitely.
What does “weight plateau” mean in research?
The SURMOUNT plateau analysis did not define plateau as “the scale did not move this week.” It used repeated longer intervals. This matters because short-term body weight can change with salt, carbohydrate, bowel contents, menstruation, travel and exercise.
When did participants plateau?
| Baseline category | Median time to plateau |
|---|---|
| Overweight | 24.3 weeks |
| Class I obesity | 26.0 weeks |
| Class II obesity | 36.1 weeks |
| Class III obesity | 36.1 weeks |
Plateau does not necessarily mean loss of drug effect
As body weight falls, energy requirements also decline. A calorie deficit that produced rapid loss early in treatment may become smaller later. The medication may still be helping appetite regulation and preventing regain even when the scale is no longer dropping quickly.
Seven things to check before increasing the dose
- Use 7-day average weight, not a single reading.
- Check constipation.
- Review drinks, alcohol and snacks.
- Check whether daily steps/activity fell.
- Review sleep and stress.
- Measure waist circumference.
- Ask whether you are already close to a healthy treatment goal.
When can escalation be reasonable?
Escalation may be reasonable after the current dose has been used for at least the labeled interval, the longer-term trend is truly insufficient for the treatment goal, and side effects, nutrition and hydration are acceptable. It is not reasonable simply to “break a plateau” with a dose increase regardless of tolerability.
What if you are already on 15 mg?
There is no higher labeled Mounjaro dose. At 15 mg, focus shifts to maintenance, food quality, activity, constipation, sleep, other weight-promoting medications and whether further weight loss is medically needed. See the 15 mg plateau guide.
Should you stop treatment to “reset” it?
There is no established “reset” strategy. In SURMOUNT-4, participants who switched from tirzepatide to placebo after substantial weight loss regained an average 14.0% from week 36 to week 88, whereas those who continued lost another 5.5% on average. Do not stop and restart on your own.
A simple 4-week plateau log
| Track | Why |
|---|---|
| 7-day average weight | Separate trend from daily noise |
| Waist | Capture non-scale change |
| Appetite/snacks | Identify behavioral return |
| Steps/exercise | Check activity drift |
| Bowel movements | Identify constipation-related “plateau” |
| Side effects | Decide whether escalation is tolerable |
Frequently asked questions
Is a Mounjaro plateau normal?
Yes. Long-term trials show that many people eventually reach a weight plateau; it does not automatically mean treatment has failed.
Should I increase the dose after one week without weight loss?
Usually not based on one week alone. Review a longer trend and other causes of short-term scale variation.
Can 15 mg also plateau?
Yes. 15 mg is the maximum labeled dose, but long-term weight loss still tends to slow and stabilize.
Should I stop Mounjaro for a while to make it work again?
There is no established reset method, and withdrawal trials show substantial average weight regain after stopping tirzepatide.
References
- PMDA. Mounjaro Japanese package insert, revision September 2026.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.
- Horn DB, et al. Time to weight plateau with tirzepatide treatment in SURMOUNT-1 and SURMOUNT-4. Clin Obes. 2025.
- Aronne LJ, et al. SURMOUNT-4. JAMA. 2024.
In Japan, Mounjaro is approved for type 2 diabetes. Use of Mounjaro for weight management is off-label. Obesity-trial data are cited as medical evidence about tirzepatide, not as a statement that Mounjaro is approved for obesity in Japan.